戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 atelet aggregation was measured by impedance aggregometry.
2 id, ADP, collagen, or epinephrine by optical aggregometry.
3 tervals for a year, using light transmission aggregometry.
4 luding flow cytometry and light transmission aggregometry.
5            Platelet function was measured by aggregometry.
6  with VerifyNow-P2Y12 and light transmission aggregometry.
7  VerifyNow-P2Y12, but not light transmission aggregometry.
8 s differences in IC(5)(0) values obtained by aggregometry.
9 nders were identified by light transmittance aggregometry.
10 gation at 6 h assessed by light-transmission aggregometry.
11 ns and measured response by ex vivo platelet aggregometry.
12 assay and heparin-induced multiple electrode aggregometry.
13 eline and steady state by light-transmission aggregometry.
14 ggregation (PA) was assessed by conventional aggregometry.
15 very of platelet function than turbidimetric aggregometry.
16 d on flow cytometry and whole blood platelet aggregometry.
17 osine diphosphate-induced light transmission aggregometry (11.6% relative increase in maximal platele
18 mbocytopenia, 18 of 18 had abnormal platelet aggregometry, 16 of 35 had decreased platelet dense gran
19 gregation between groups (multiple electrode aggregometry, 17.6+/-7.2 versus 18.1+/-6 U; P=0.281).
20  assessed with the use of light transmission aggregometry, a point-of-care P2Y(12) platelet-reactivit
21 2 reaction units [PRU]), light transmittance aggregometry (adenosine diphosphate 5 and 20 mumol/l and
22                          Light transmittance aggregometry (adenosine diphosphate 5 to 20 muM), Verify
23 imuli were assessed with light transmittance aggregometry and defined patients with high post-treatme
24 -deficient platelets were confirmed via lumi-aggregometry and FACS analysis for P-selectin and LAMP-1
25 elets, as determined by whole blood platelet aggregometry and flow cytometric analysis of the platele
26                        Whole blood impedance aggregometry and flow cytometry evaluated platelet aggre
27                                     Platelet aggregometry and flow cytometry in a subset of subjects
28                                              Aggregometry and flow cytometry were used to assess plat
29 -leukocyte interaction were analyzed by lumi-aggregometry and flow cytometry.
30       Neutrophil aggregation was measured by aggregometry and leukergy.
31 gation was measured using multiple electrode aggregometry and standard light transmission aggregometr
32 ion than patients without ischemic events by aggregometry and TEG (p < 0.001 for both measurements).
33 treatment platelet reactivity as measured by aggregometry and TEG were the only variables significant
34 treatment platelet reactivity at baseline by aggregometry and TEG, respectively.
35 telet Analyzer (CPA), with in vitro platelet aggregometry and the Rapid Platelet Function Assay (RPFA
36 t between heparin-induced multiple electrode aggregometry and the serotonin release assay was at 0.90
37 ion measured by standard light transmittance aggregometry and thrombelastography (TEG) will be at inc
38 latelet reactivity measured by turbidometric aggregometry and thrombin-induced platelet-fibrin clot s
39 tivation of platelets by CRP and collagen in aggregometry and thrombus formation by the latter in who
40  1 h, 4 h, and 24 h using light transmission aggregometry and vasodilator-stimulated phosphoprotein p
41 to comprehensive analyses by flow cytometry, aggregometry, and immunoblotting.
42 imulated phosphoprotein, light transmittance aggregometry, and Multiplate were similar between prasug
43 imulated phosphoprotein, light transmittance aggregometry, and Multiplate, which allowed us to explor
44 we have developed a miniaturized whole blood aggregometry assay, based on a readily accessible 96-wel
45  aggregation (20 muM) by light transmittance aggregometry at 1 week (primary end point) was lower aft
46 latelet reactivity was assessed by impedance aggregometry before loading (intrinsic platelet reactivi
47 nction was shown by flow cytometry, platelet aggregometry, bleeding assays, and intravital imaging of
48 y 3 and Day 42 post-MI), light transmittance aggregometry, bleeding time, and histological and molecu
49                                     In vitro aggregometry confirmed that sildenafil rendered platelet
50 nt-of-care tests (thrombelastometry/platelet aggregometry), conventional coagulation tests, whole blo
51 n optimal heparin-induced multiple electrode aggregometry cut-off at 1,300 AU x minutes (specificity,
52 known as "heparin-induced multiple electrode aggregometry." DESIGN: In this observational prospective
53 tomic force microscopy (small contact zone), aggregometry (discrete interactions), micropipette manip
54 Human platelet activation was assessed using aggregometry, flow cytometry, western blot analysis, tot
55 function was monitored with the CPA and with aggregometry for up to 1 week after abciximab administra
56  diphosphate was measured with turbidimetric aggregometry in both D-phenylalanyl-L-prolyl-L-arginine
57 ich was 30-minute IPA at light transmittance aggregometry in response to 20 mumol/L adenosine diphosp
58 optimization of older tests such as platelet aggregometry, in addition to better defining the role of
59        Platelet-rich plasma was obtained for aggregometry induced by collagen (1 to 10 micrograms/ml)
60           Heparin-induced multiple electrode aggregometry is a reliable and rapid platelet functional
61 aggregometry and standard light transmission aggregometry just before the switch and at 2, 6, 24, and
62 ine diphosphate (ADP) by light transmittance aggregometry (LTA) in patients undergoing PCI (n = 192).
63                           Light transmission aggregometry (LTA) is used worldwide for the investigati
64           Assays included light transmission aggregometry (LTA), VerifyNow P2Y12 (VN), and vasodilato
65           Assays included light transmission aggregometry (LTA), VerifyNow P2Y12 (VN-P2Y12), and vaso
66 tery disease (CAD) using light transmittance aggregometry (LTA), VerifyNow, platelet function analyze
67 efects in comparison with light transmission aggregometry (LTA).
68 egation was measured with light transmission aggregometry (LTA); platelet activation was assessed by
69 2 (P(2)Y(1)(2)) assay and multiple electrode aggregometry (MEA).
70 were assessed by means of light transmission aggregometry of suspensions with varying ratios of plate
71         Over 5 years, we have performed lumi-aggregometry on 9 platelet agonists in 111 unrelated res
72 platelet aggregation was assessed by optical aggregometry on day 1 and at 4-week intervals.
73  is more severe in LAD-III patients, classic aggregometry or perfusion of Glanzmann or LAD-III platel
74 ntage of free GP IIb/IIIa receptors than was aggregometry or the RPFA.
75 ost-dose, as measured by light transmittance aggregometry or vasodilator-stimulated phosphoprotein as
76           Heparin-induced multiple electrode aggregometry performed very well in heparin-induced thro
77  NAC thrombolytic effect, including platelet aggregometry, platelet-rich thrombi lysis assays, thromb
78 gregation was evaluated by in vitro platelet aggregometry (Protocol 3).
79 e studied with Fura-2 and light transmission aggregometry, respectively.
80         The mean maximum light transmittance aggregometry responses (adenosine diphosphate 20 muM) po
81                         Whole blood platelet aggregometry revealed a significant reduction of platele
82 rimental techniques (i.e. multiple electrode aggregometry, rotational thromboelastometry, immunofluor
83 eference, heparin-induced multiple electrode aggregometry showed an excellent negative predictive val
84                               Cone and plate aggregometry showed that compared with Phe2561, Tyr2561
85                    Ex vivo, the CPA, but not aggregometry, showed prolonged platelet inhibition with
86 ated platelet function assessed by classical aggregometry, single-particle counting, granule secretio
87 , imatinib produce abnormalities in platelet aggregometry testing.
88                    When assessed by platelet aggregometry, the disruption of the lysin gene in SF100
89                     Using light transmission aggregometry, the extent of aggregation induced by plate
90  aggregation and activation were assessed by aggregometry, thromboxane B2 assay, or FACS.
91  days, and 14 days using light transmittance aggregometry, VerifyNow P2Y(12) assay, and vasodilator-s
92 schemic risk measured by light transmittance aggregometry, VerifyNow P2Y(12) assay, and vasodilator-s
93  difference in measurements between RPFA and aggregometry was -4% (+/-4% SD), and the mean difference
94           Heparin-induced multiple electrode aggregometry was assessed against heparin-induced thromb
95 utant mice, whereas platelet shape change in aggregometry was attenuated.
96          Neutrophil aggregation, measured by aggregometry, was increased in SS patients, 16 +/- 4% (p
97 results were found using light transmittance aggregometry with 5 muM adenosine diphosphate, VerifyNow
98 t fibrinogen binding, and light transmission aggregometry with ADP 5 and 10 mumol/l recorded at maxim
99 66 abolished ADP-induced light transmittance aggregometry without affecting bleeding time.